Literature DB >> 25109815

Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients.

Cinzia Cordioli1, Nicola De Rossi, Sarah Rasia, Giovanni Lodoli, Ruggero Capra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25109815     DOI： 10.1007/s10072-014-1918-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  9 in total

1.  Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.

Authors:  Nicholas F Blair; Bruce J Brew; Jean-Pierre Halpern
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

Authors:  Rémy Phan-Ba; Emilie Lommers; Luaba Tshibanda; Philippe Calay; Bernard Dubois; Gustave Moonen; David Clifford; Shibeshih Belachew
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-10-19       Impact factor: 10.154

3.  Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Authors:  I L Tan; J C McArthur; D B Clifford; E O Major; A Nath
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

4.  Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere.

Authors:  Igor J Koralnik; David B Clifford
Journal:  Neurology       Date:  2012-11-21       Impact factor: 9.910

5.  Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies.

Authors:  Dirk Mentzer; Jürgen Prestel; Ortwin Adams; Ralf Gold; Hans-Peter Hartung; Hartmut Hengel; Bernd C Kieseier; Wolf-Dieter Ludwig; Brigitte Keller-Stanislawski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-17       Impact factor: 10.154

6.  Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

Authors:  Morten Blinkenberg; Finn Sellebjerg; Anne-Mette Leffers; Camilla Gøbel Madsen; Per Soelberg Sørensen
Journal:  Mult Scler       Date:  2013-03-18       Impact factor: 6.312

7.  PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids.

Authors:  K Tan; R Roda; L Ostrow; J McArthur; A Nath
Journal:  Neurology       Date:  2009-01-07       Impact factor: 9.910

8.  Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

Authors:  Caroline Antoniol; Samantha Jilek; Myriam Schluep; Noëlle Mercier; Mathieu Canales; Géraldine Le Goff; Claudia Campiche; Giuseppe Pantaleo; Renaud A Du Pasquier
Journal:  Neurology       Date:  2012-11-21       Impact factor: 9.910

9.  Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS).

Authors:  David M Murdoch; Melinda S Suchard; Willem D F Venter; Patrick Mhlangu; Janet S Ottinger; Charles Feldman; Annelies Van Rie; Deborah K Glencross; Wendy S Stevens; Kent J Weinhold
Journal:  AIDS Res Ther       Date:  2009-07-16       Impact factor: 2.250
  9 in total
  1 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.